British company Oxford Biomedica has said the Serum Institute of India (SII) will invest $68 million in it to help fund the development of a plant that manufactures Covid-19 shots, Reuters reports.
SII — the world’s largest vaccine manufacturer by volume — and Oxford Biomedica both produce AstraZeneca’s Covid-19 vaccine.
Oxford Biomedica said it would use the funds to develop the fallow area at its Oxbox plant into a manufacturing space expected to come online in mid-2023.
The Oxbox plant currently makes Covid-19 shots, and the new space is expected to include a capacity to produce viral vector-based products including vaccines, Biomedica said.
